Exelixis Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Excellent. So welcome to the day 2 of our Biotech Focus Conference. We're very privileged to have the Chief Scientific Officer, Peter Lamb, to kind of talk about this evolution of Exelixis. So before, as you look into the history, the company was doing genetic works and then evolve into a small molecule expert and now expanding into the biologics world with either modified antibody or ADC. So I believe it's the first time that you'll give us a very in-depth overview of this effort. So I appreciate that, Peter, and I'll turn the floor to you.
Great. Thanks, Andy. Really appreciate the opportunity to present today. And as you said, I will be focusing really on our kind of strategy and progress in terms of building a next-generation oncology pipeline, kind of following on behind cabozantinib.
The usual safe harbor. So I'll just start with sort of a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
